Reading KTTA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KTTA free→Reading KTTA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KTTA free→QuarterlyIQ Insights · KTTA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Medical Officer On May 4, 2026, Pasithea Therapeutics Corp. (the “Company”) announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026. Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requ…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 28, 2026, at a Special Meeting of Stockholders (the “Special Meeting”) of Pasithea Therapeutics Corp. (the “Company”), the Company’s stockholders approved an amendment (the “Plan Amendment”) to the Company’s 2023 Stock Incentive Plan, as amended (the “2023 Incentive Plan”), increasing the number of shares authorized for issuance under th…
Other Events. On November 20, 2025, the Company issued a press release (the “November 20 Press Release”) relating to positive interim Phase 1 data from its ongoing first-in-human clinical trial of PAS-004 in patients with advanced solid tumors driven by MAPK pathway alterations, including documented RAS, NF1 or RAF mutations, and in patients who have failed prior BRAF/MEK inhibition. The Company released the below interim Phase 1 results for PAS-004 in the Press Release: Initial Signals of Cl…
Other Events. On November 4, 2025, the Company issued a press release (the “Press Release”) relating to its Phase 1/1b open-label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PAS-004 in adult participants with neurofibromatosis type 1 (NF1), announcing the activation of a new U.S. clinical trial site at the University of Alabama at Birmingham (“UAB”). Enrollment at the UAB site is expected to begin immediately. The Company also announced that it…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 24, 2025, the Board of Directors (the “Board”) of Pasithea Therapeutics Corp. (the “Company”) approved the following compensation arrangements for the Company’s executive officers and directors. After consulting with a compensation consultant and considering the compensation arrangements for executive officers and directors among the Com…
Other Events. On September 16, 2025, the Company issued a press release (the “Press Release”) relating to its Phase 1/1b open-label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PAS-004 in adult participants with neurofibromatosis type 1 (NF1) (the “NF1 Trial”), announcing the activation of two clinical trial sites in South Korea—Asan Medical Centre and Severance Hospital Yonsei University Health System. These sites are now actively recruiting tr…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 3, 2025, at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Pasithea Therapeutics Corp. (the “Company”), the Company’s stockholders approved an amendment (the “Plan Amendment”) to the Company’s 2023 Stock Incentive Plan (the “2023 Incentive Plan”) increasing the number of shares authorized for issuance under the 2023…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On June 23, 2025, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirem…
Other Events. On June 20, 2025, Pasithea Therapeutics Corp. (the “Company”) increased the maximum aggregate offering price of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) issuable under the At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, dated November 26, 2024, from $2,076,000 to $4,227,000 and filed a prospectus supplement (the “Current Prospectus Supplement”) to register an aggregate of $2,151,000 of ad…
Changes in Registrant’s Certifying Accountant. Based on information provided by Marcum LLP (“Marcum”), the independent registered public accounting firm of Pasithea Therapeutics Corp., a Delaware corporation (the “Company”), CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company’s independent registered public accounting firm through April 23, 2025. On April 23, 2025, the Company dismissed Marcum as the Company’s in…
Importance-ranked changes since the prior daily snapshot.
Total stock risk rose by 16.4 points (from 15.8 to 32.2).
Market risk rose by 16.4 points (from 15.8 to 32.2).
risk label changed from 'low' to 'moderate'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.